Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Senl-h19 by Hebei Senlang Biotechnology for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
Senl-h19 is under clinical development by Hebei Senlang Biotechnology and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell...